B. Braun meets targets and drives innovation

• Group sales increase by 5.1 percent at constant currencies to € 9.4 billion

• EBITDA margin reaches 13.0 percent; profit before taxes rise to 4.9 percent of sales
  
  
• € 1.4 billion invested in R&D, the global production network, and technologies
   

“2025 was a successful year for B. Braun. Across every area of care, our customers’ needs were our priority – always with the goal that as many people as possible receive high quality medical care. We met our financial targets and further strengthened our position as a leading medical technology company,” says Anna Maria Braun, CEO of B. Braun SE. “In 2026, we will continue to execute on our long- term Group strategy with discipline and consistently leverage the opportunities of technology and digitalization – both in our internal processes and in product development for our customers”.

Group performance in 2025

In the reporting year, B. Braun generated sales of € 9.4 billion (prior year: € 9.1 billion). The increase amounted to 5.1 percent at constant currencies (+2.8 percent in Group currency), reaching the strategic target corridor of 5 to 7 percent. All three divisions and each of the six business regions contributed to this growth.

Particularly dynamic momentum came from consumables, regional anesthesia products, neurosurgery and minimally invasive surgery, as well as from health care centers and the stoma and continence care portfolio.

By region, B. Braun achieved the strongest sales increase in Asia-Pacific with +8.1 percent at constant currencies, followed by Eastern Europe with +6.7 percent. Looking at the divisions, the largest division, Hospital Care, recorded the strongest growth with +6.1 percent at constant currencies, followed by Aesculap with +5.4 percent and Avitum with +2.1 percent.

B. Braun also further strengthened its profitability in the reporting year: earnings before interest, taxes, depreciation and amortization (EBITDA) increased to€ 1,219.5 million, up from € 1,088.9 million in the previous year. The corresponding margin improved by 1.1 percentage points to 13.0 percent. Profit before taxes rose to € 460.9 million (previous year: € 257.0 million) and thus reached 4.9 percent of sales. Net income amounted to € 307.2 million, up from € 165.3 million in the comparative period, which had been impacted by non-recurring effects.

Key drivers of this positive development were focused portfolio management, disciplined cost control, and efficiency gains across plants worldwide. Headwinds from currency effects and tariffs were largely offset by positive impacts from price adjustments and necessary adjustments to asset depreciation periods.

B. Braun’s key balance sheet and financial indicators remain at a solid level.
As of December 31, 2025, the equity ratio stood at 48.0 percent, up from 46.1 percent at year-end 2024.

Significant investments in the production network and technologies

In 2025, B. Braun once again invested substantially in its global infrastructure. More than € 800 million were invested in expansions and the digitalization of the global production network as well as in new technologies.

In October 2025, B. Braun commissioned the highly automated ACTIVE plant for infusion therapy single-use products in Melsungen. The new facility uses, among other things, robotics and automated guided vehicle systems. In Tuttlingen, the company laid the foundation for the Technology Factory, which is redesigning the pre-production of surgical products. Looking ahead, the facility is designed for carbon-neutral operations – including geothermal energy, process waste heat, and photovoltaics. With the full acquisition of U.S.-based microsurgery specialist True Digital Surgery, B. Braun also expanded its technology portfolio for robot-assisted 3D microscopy in neurosurgery, spine surgery, and ENT procedures. In addition, by expanding and making targeted acquisitions in the area of health care centers in Romania and the Czech Republic, B. Braun further strengthened its capacities in dialysis care.

R&D: An innovative portfolio with integrated solutions

In 2025, the company increased its spending on research and development to € 584 million – an increase of 11 percent. This meant B. Braun invested 6.2 percent of sales in R&D and innovation.

Technology and digitalization will shape the future of health care. B. Braun is therefore continuously evolving its portfolio toward integrated, digitally connected solutions that bring together devices, software, consumables, and services into an intelligent, end-to-end system. In infusion therapy, connectivity between infusion pumps, related accessories, and software was further advanced. The resulting integrated solution enables reliable adherence to therapy as well as automated documentation – an important contribution to patient safety and a meaningful relief for nursing staff. In surgery, B. Braun strengthens standardization of operating room workflows from planning through documentation with an integrated solution. Real-time data supports more precise decisions, while a digitally controlled sterile supply management solution makes preparation more efficient and predictable. In dialysis, automated data capture and documentation significantly reduces the administrative burden, freeing up more time for individualized patient care.

A strong team of more than 66,000 employees

At year-end 2025, B. Braun employed 66,821 people from 143 nations in64 countries. This represents the creation of around 1,000 additional positions, primarily in research and development and sales. At the same time, B. Braun advanced cross-divisional and cross-country collaboration across the Group to bundle expertise more effectively and bring innovations to market faster.

“Integrated solutions are created when experts from medicine, engineering, digitalization, production, and sales work closely together. This interaction reduces interfaces, shortens development cycles, and brings innovations to patients faster,” says CEO Anna Maria Braun.

Outlook

Looking ahead, B. Braun has set ambitious targets and expects continued profitable growth. The company’s longterm strategy targets annual sales growth of 5 to 7 percent on a currency -adjusted basis, in line with its strategic corridor. On the earnings side, B. Braun aims to continue to gradually increase its EBITDA margin and profit before taxes.

About B. Braun

With more than 66,000 employees, B. Braun is a true partner, developing integrated solutions, and setting new standards to drive advancements in health care. In 2025, B. Braun generated sales of € 9.4 billion.

For more information, visit www.bbraun.com or follow us on LinkedIn, Instagram, and Facebook.